



RECEIVED

APR 21 2000

TECH CENTER 1600/2900

APR 17 2000

TECH CENTER 1600/2900

PATENT
ocket No. 415852000100

SP 1645 # Box SQWD

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on April 7, 2000.

Denise Lade

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Jeffrey John Gorman

Serial No.: 09/202,035

Filing Date: December 4, 1998

For: VIRAL PEPTIDES WITH
STRUCTURAL HOMOLOGY TO
PROTEIN G OF RESPIRATORY
SYNCYTIAL VIRUS

Examiner: B. Nelson

Group Art Unit: 1645

#8a 4/22/00
Bray

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES**

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Please enter the following Sequence Listing, amendments and remarks.

Remarks

The printed Sequence Listing is identical to the Sequence Listing submitted in machine-readable form.

This paper is submitted to comply with the United States Patent Office rules governing gene sequences. No new matter is added.




In the unlikely event that the transmittal letter is separated from this sequence listing and the U.S. Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this sequence listing to our Deposit Account No. 03-1952. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: April 7, 2000

By:


Gladys H. Monroy
Registration No. 32,430

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5711
Facsimile: (650) 494-0792

RECEIVED

APR 21 2000

TECH CENTER 1500/2800



SEQUENCE LISTING

<110> Jeffrey John Gorman

<120> Viral Peptides with Structural Homology to Protein G of Respiratory Syncytial Virus

<130> 415852000100

<140> US 09/202,035

<141> 1998-12-04

<150> PCT/AU97/00351

<151> 1997-06-04

<150> AU PO 0265

<151> 1996-06-05

<160> 44

<170> PatentIn Ver. 2.1

<210> 1

<211> 49

<212> PRT

<213> respiratory syncytial virus

<400> 1

Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His

1 5 10 15

Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro

20 25 30

Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys

35 40 45

Lys

<210> 2

<211> 49

<212> PRT

<213> respiratory syncytial virus

<400> 2

Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn Asn Asp Phe His

1 5 10 15

Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro

20 25 30

Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys

35 40 45

Lys

<210> 3

<211> 49

<212> PRT

<213> respiratory syncytial virus

<400> 3

Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
20 25 30
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys
35 40 45
Arg

<210> 4

<211> 49

<212> PRT

<213> respiratory syncytial virus

<400> 4

Lys Gln His Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
20 25 30
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys
35 40 45
Lys

<210> 5

<211> 49

<212> PRT

<213> respiratory syncytial virus

<400> 5

Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
20 25 30
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys
35 40 45
Lys

<210> 6

<211> 49

<212> PRT

<213> respiratory syncytial virus

<400> 6

Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
20 25 30
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys
35 40 45
Lys

<210> 7
<211> 49
<212> PRT
<213> respiratory syncytial virus

<400> 7
Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
20 25 30
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys
35 40 45
Lys

<210> 8
<211> 49
<212> PRT
<213> respiratory syncytial virus

<400> 8
Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
20 25 30
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys
35 40 45
Arg

<210> 9
<211> 49
<212> PRT
<213> respiratory syncytial virus

<400> 9
Lys Ser Arg Ser Lys Asn Pro Pro Lys Lys Pro Lys Asp Asp Tyr His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Gly Asn Asn Gln
20 25 30
Leu Cys Lys Ser Ile Cys Lys Thr Ile Pro Ser Asn Lys Pro Lys Lys
35 40 45
Lys

<210> 10
<211> 49
<212> PRT
<213> respiratory syncytial virus

<400> 10
Lys Ser Arg Ser Lys Asn Pro Pro Lys Lys Pro Lys Asp Asp Tyr His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Gly Asn Asn Gln
20 25 30
Leu Cys Lys Ser Ile Cys Lys Thr Ile Pro Ser Asn Lys Pro Lys Lys

35 40 45
 Lys
 <210> 11
 <211> 49
 <212> PRT
 <213> respiratory syncytial virus
 <400> 11
 Lys Pro Arg Pro Lys Asn Pro Pro Lys Lys Pro Lys Asp Asp Tyr His
 1 5 10 15
 Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Gly Asn Asn Gln
 20 25 30
 Leu Cys Lys Ser Ile Cys Lys Thr Ile Pro Ser Asn Lys Pro Lys Lys
 35 40 45
 Lys

<210> 12
 <211> 49
 <212> PRT
 <213> respiratory syncytial virus
 <400> 12
 Lys Pro Arg Leu Lys Asn Pro Pro Lys Lys Pro Lys Asp Asp Tyr His
 1 5 10 15
 Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Gly Asn Asn Gln
 20 25 30
 Leu Cys Lys Ser Ile Cys Lys Thr Ile Pro Ser Asn Lys Pro Lys Lys
 35 40 45
 Lys

<210> 13
 <211> 49
 <212> PRT
 <213> respiratory syncytial virus
 <400> 13
 Lys Pro Arg Leu Lys Asn Pro Pro Lys Lys Pro Lys Asp Asp Tyr His
 1 5 10 15
 Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Gly Asn Asn Gln
 20 25 30
 Leu Cys Lys Ser Ile Cys Lys Thr Ile Ser Ser Asn Lys Pro Lys Lys
 35 40 45
 Lys

<210> 14
 <211> 49
 <212> PRT
 <213> respiratory syncytial virus
 <400> 14
 Lys Pro Arg Leu Lys Asn Pro Pro Lys Lys Pro Lys Asp Asp Tyr His

1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Gly Asn Asn Gln
20 25 30
Leu Cys Lys Ser Ile Cys Lys Thr Ile Pro Ser Asn Lys Pro Lys Lys
35 40 45
Lys

<210> 15
<211> 49
<212> PRT
<213> respiratory syncytial virus

<400> 15
Lys Ser Arg Ser Lys Asn Pro Pro Lys Lys Pro Lys Asp Asp Tyr His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Gly Asn Asn Gln
20 25 30
Leu Cys Lys Ser Ile Cys Lys Thr Ile Pro Ser Asn Lys Pro Lys Lys
35 40 45
Lys

<210> 16
<211> 49
<212> PRT
<213> respiratory syncytial virus

<400> 16
Asn Pro Ser Gly Ser Ile Pro Pro Glu Asn His Gln Asp His Asn Asn
1 5 10 15
Phe Gln Thr Leu Pro Tyr Val Pro Cys Ser Thr Cys Glu Gly Asn Leu
20 25 30
Ala Cys Leu Ser Leu Cys His Ile Glu Thr Glu Arg Ala Pro Ser Arg
35 40 45
Ala

<210> 17
<211> 49
<212> PRT
<213> respiratory syncytial virus

<400> 17
Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Pro Val Pro Cys Ser Thr Cys Ser Asn Asn Pro
20 25 30
Thr Arg Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys
35 40 45
Lys

<210> 18
<211> 49
<212> PRT

<213> respiratory syncytial virus

<400> 18

Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His

1 5 10 15

Phe Glu Val Ser Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro

20 25 30

Thr Cys Trp Ala Ile Arg Lys Arg Thr Pro Asn Lys Lys Pro Gly Lys

35 40 45

Lys

<210> 19

<211> 35

<212> PRT

<213> respiratory syncytial virus

<220>

<221> DISULFID

<222> (22)..(35)

<220>

<221> DISULFID

<222> (25)..(31)

<400> 19

Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His Phe Glu Val

1 5 10 15

Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Pro Thr Cys Trp Ala

20 25 30

Ile Cys Lys

35

<210> 20

<211> 36

<212> PRT

<213> respiratory syncytial virus

<400> 20

Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His Phe Glu Val

1 5 10 15

Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys Trp

20 25 30

Ala Ile Cys Lys

35

<210> 21

<211> 15

<212> PRT

<213> respiratory syncytial virus

<220>

<221> DISULFID

<222> (5)

<223> to residue 3 of sequence ID 22

<220>

<221> DISULFID

<222> (8)..(14)

<400> 21

Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys Trp

1

5

10

15

<210> 22

<211> 4

<212> PRT

<213> respiratory syncytial virus

<220>

<221> DISULFID

<222> (3)

<223> to residue 5 of sequence ID 21

<400> 22

Ala Ile Cys Lys

1

<210> 23

<211> 15

<212> PRT

<213> respiratory syncytial virus

<400> 23

Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys Trp

1

5

10

15

<210> 24

<211> 19

<212> PRT

<213> respiratory syncytial virus

<220>

<221> DISULFID

<222> (5)..(18)

<220>

<221> DISULFID

<222> (8)..(14)

<400> 24

Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys Trp Ala

1

5

10

15

Ile Cys Lys

<210> 25

<211> 19

<212> PRT

<213> respiratory syncytial virus

<400> 25

Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys Trp Ala

1

5

10

15

Ile Cys Lys

<210> 26

<211> 10

<212> PRT

<213> respiratory syncytial virus

<220>

<221> DISULFID

<222> (2)..(8)

<400> 26

Ile Cys Ser Asn Asn Pro Thr Cys Trp Ala

1

5

10

<210> 27

<211> 15

<212> PRT

<213> respiratory syncytial virus

<400> 27

Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys Trp Ala Ile Cys Lys

1

5

10

15

<210> 28

<211> 11

<212> PRT

<213> respiratory syncytial virus

<220>

<221> DISULFID

<222> (1)

<223> to residue 3 of sequence ID 29

<220>

<221> DISULFID

<222> (4)..(10)

<400> 28

Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys Trp

1

5

10

<210> 29

<211> 4

<212> PRT

<213> respiratory syncytial virus

<220>

<221> DISULFID

<222> (3)

<223> to residue 1 of sequence ID 28

<400> 29

Ala Ile Cys Lys

1

<210> 30
 <211> 15
 <212> PRT
 <213> respiratory syncytial virus
 <220>
 <221> DISULFID
 <222> (5)
 <223> to residue 3 of sequence ID 31
 <220>
 <221> DISULFID
 <222> (8)..(14)

<400> 30
 Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys Trp
 1 5 10 15

<210> 31
 <211> 4
 <212> PRT
 <213> respiratory syncytial virus
 <220>
 <221> DISULFID
 <222> (3)
 <223> to residue 5 of sequence ID 30

<400> 31
 Ala Ile Cys Lys
 1

<210> 32
 <211> 49
 <212> PRT
 <213> respiratory syncytial virus

<400> 32
 Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His
 1 5 10 15
 Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
 20 25 30
 Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys
 35 40 45
 Lys

<210> 33
 <211> 49
 <212> PRT
 <213> respiratory syncytial virus

<400> 33
 Lys Ser Arg Ser Lys Asn Pro Pro Lys Lys Pro Lys Asp Asp Tyr His
 1 5 10 15
 Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Gly Asn Asn Gln

20 25 30
 Leu Cys Lys Ser Ile Cys Lys Thr Ile Pro Ser Asn Lys Pro Lys Lys
 35 40 45
 Lys

<210> 34
 <211> 49
 <212> PRT
 <213> respiratory syncytial virus

<400> 34
 Asn Pro Ser Gly Ser Ile Pro Pro Glu Asn His Gln Asp His Asn Asn
 1 5 10 15
 Phe Gln Thr Leu Pro Tyr Val Pro Cys Ser Thr Cys Glu Gly Asn Leu
 20 25 30
 Ala Cys Leu Ser Leu Cys His Ile Glu Thr Glu Arg Ala Pro Ser Arg
 35 40 45
 Ala

<210> 35
 <211> 49
 <212> PRT
 <213> respiratory syncytial virus

<400> 35
 Ser Ser Gln Lys Ser Asn Pro Ser Glu Ile Gln Gln Asp Tyr Ser Asp
 1 5 10 15
 Phe Gln Ile Leu Pro Tyr Val Pro Cys Asn Ile Cys Glu Gly Asp Ser
 20 25 30
 Ala Cys Leu Ser Leu Cys Gln Asp Arg Ser Glu Ser Ile Leu Asp Lys
 35 40 45
 Ala

<210> 36
 <211> 49
 <212> PRT
 <213> respiratory syncytial virus
 <220>
 <221> SITE
 <222> (1)
 <223> acetylation
 <220>
 <221> SITE
 <222> (49)
 <223> amidation

<400> 36
 Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His
 1 5 10 15
 Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
 20 25 30
 Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys
 35 40 45

Lys

<210> 37
<211> 42
<212> PRT
<213> respiratory syncytial virus
<220>
<221> SITE
<222> (1)
<223> acetylation
<220>
<221> SITE
<222> (42)
<223> amidation

<400> 37
Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
20 25 30
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro
35 40

<210> 38
<211> 35
<212> PRT
<213> respiratory syncytial virus
<220>
<221> SITE
<222> (1)
<223> acetylation
<220>
<221> SITE
<222> (35)
<223> amidation

<400> 38
Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn
1 5 10 15
Asn Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro
20 25 30
Gly Lys Lys
35

<210> 39
<211> 29
<212> PRT
<213> respiratory syncytial virus
<220>
<221> SITE
<222> (1)
<223> acetylation
<220>

<221> SITE
<222> (29)
<223> amidation

<400> 39
Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Gly
20 25

<210> 40
<211> 49
<212> PRT
<213> respiratory syncytial virus
<220>
<221> SITE
<222> (1)
<223> fluorescein isothiocarbamyl beta-alanine
derivatisation
<220>
<221> SITE
<222> (49)
<223> amidation

<400> 40
Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
20 25 30
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn/Lys Lys Pro Gly Lys
35 40 45
Lys

<210> 41
<211> 35
<212> PRT
<213> respiratory syncytial virus
<220>
<221> SITE
<222> (1)
<223> fluorescein isothiocarbamyl beta-alanine
derivatisation
<220>
<221> SITE
<222> (35)
<223> amidation

<400> 41
Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn
1 5 10 15
Asn Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro
20 25 30
Gly Lys Lys
35

<210> 42
<211> 49
<212> PRT
<213> respiratory syncytial virus
<220>
<221> SITE
<222> (1)
<223> benzoyl benzylamide derivatisation
<220>
<221> SITE
<222> (49)
<223> amidation

<400> 42
Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
20 25 30
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys
35 40 45
Lys

<210> 43
<211> 49
<212> PRT
<213> respiratory syncytial virus
<220>
<221> SITE
<222> (1)
<223> biotinyl amide derivatisation
<220>
<221> SITE
<222> (49)
<223> amidation

<400> 43
Lys Gln Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His
1 5 10 15
Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro
20 25 30
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys
35 40 45
Lys


<210> 44
<211> 14
<212> PRT
<213> respiratory syncytial virus
<220>
<221> SITE
<222> (1)
<223> fluorescein isothiocarbamyl beta-alanine

derivatisation
<400> 44
Val Thr Arg Gln Arg Arg Ala Arg Asn Gly Ala Ser Arg Ser
1 5 10

all
cont

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE